Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE Recently, accumulated evidence indicates that the enhancer of zeste homologue 2 (EZH2) is highly expressed in a wide range of cancer types, including NSCLC. 30527357

2019

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE We further discuss EZH2 inhibitors that are now showing early signs of promise in clinical trials and also additional strategies to combat roles of EZH2 in cancer. 26845405

2016

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE EZH2 is essential for glioblastoma cancer stem cell maintenance. 19934320

2009

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE EZH2 mediates interaction with several long non-coding RNAs (lncRNAs) to modulate epithelial-mesenchymal transition and cancer stemness, phenomena commonly associated with drug resistance. 29048549

2017

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The present study indicated that miR‑92b and EZH2 may serve as potential biomarkers for cancer detection and highlighted their possible therapeutic implications. 30066891

2018

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Numerous chemical entities have been studied as EZH2 inhibitors in the recent years and some of them entered the cancer clinical arena. 28394193

2017

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. 21539681

2011

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE In cancer EZH2 has been implicated in silencing tumor suppressor genes. 26936398

2016

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Better understanding of the molecular basis of such regulations in various cancer types will help establish EZH2-mediated epigenetic silencing as a therapeutic target. 21175789

2011

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Clinicopathologic characteristics and oncologic outcomes (recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS)) were compared, stratified by EZH2 positivity. 29748098

2018

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Moreover, low EZH2 expression was independently associated with shorter PFS in patients with cancer, suggesting that EZH2 expression is a useful additional prognostic biomarker for anti-EGFR therapy. 28147317

2017

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Overall, our results highlight EZH2 as a rational target for therapeutic intervention in sunitinib-resistant ccRCC as well as a predictive marker for RTKi response in this disease.<i>Cancer Res; 77(23); 6651-66.©2017 AACR</i>. 28978636

2017

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE A growing number of data suggests that overexpression of EZH2 associates with progression and poor outcome in a large number of cancer cases. 30510924

2018

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE EZH2, the catalytic subunit of polycomb repressor complex 2, has oncogenic properties, whereas RASSF2A, a Ras association domain family protein, has a tumor suppressor role in many types of human cancer. 27436059

2016

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 PosttranslationalModification BEFREE EZH2-dependent H2BK120 methylation in cancer cells was confirmed with an H2BK120 methylation-specific antibody. 24339737

2013

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE Lower expression of the SMARCA2 paralog was associated with cellular sensitivity to EZH2 inhibition in SMARCA4 mutant cancer models, independent of tissue derivation. 29087303

2017

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE EZH2 expression in cancer cells was significantly higher than in normal ductal pancreatic cells and fibroblasts. 22622284

2012

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE Enhancer of zeste homolog 2 (EZH2), a critical component of the polycomb repressive complex 2, has been found to be associated with multiple biological processes and is overexpressed in multiple types of cancer. 29805666

2018

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 GeneticVariation BEFREE The enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. 19904743

2010

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. 29669287

2018

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 (PRC2), possesses histone N-methyltransferase (HMT) activity and plays an essential role in cancer initiation and development. 31366503

2019

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE The most important findings of our meta-analysis was that cancer tissues exhibited higher expression levels of EZH2 protein than normal, adjacent and benign tissues (cancer tissues vs normal tissues: OR = 32.15, 95 % CI 22.58 ~ 45.79, P < 0.001; cancer tissues vs adjacent tissues: OR = 16.10, 95 % CI 11.35 ~ 22.84, P < 0.001; cancer tissues vs benign tissues: OR = 2.66, 95 % CI 1.89 ~ 3.75, P < 0.001; respectively). 24705718

2014

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE The histone methyltransferase, enhancer of zeste homologue 2 (EZH2), has recently been suggested to play a critical role in the tumorigenesis of several types of human cancer. 24212330

2014

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 Biomarker BEFREE Targeting EZH2 for cancer therapy: progress and perspective. 25854924

2015

Entrez Id: 2146
Gene Symbol: EZH2
EZH2
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.100 AlteredExpression BEFREE We found that ectopic overexpression of EZH2-regulated miRNAs attenuated cancer cell growth and invasiveness, and abrogated cancer stem cell properties. 21840484

2011